ENDV: AI 评分 43/100 — AI 分析 (4月 2026)

Endonovo Therapeutics, Inc. is a biotechnology company focused on developing and distributing non-invasive Electroceutical medical devices for regenerative medicine. Their primary product, SofPulse, targets soft tissue injuries, chronic wounds, and post-operative pain.

Key Facts: AI Score: 43/100 Sector: Healthcare

公司概况

概要：

Endonovo Therapeutics, Inc., operating in the biotechnology sector, develops and distributes non-invasive Electroceutical medical devices, including SofPulse, for regenerative medicine applications. The company targets palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain, positioning itself within the electroceuticals market.

ENDV是做什么的？

Endonovo Therapeutics, Inc., founded in 2008 and headquartered in Woodland Hills, California, is a biotechnology company specializing in the development, manufacture, and distribution of non-invasive Electroceutical medical devices. The company's core focus is regenerative medicine, with a mission to provide innovative solutions for various medical conditions through its proprietary technology. Its flagship product, SofPulse, is a non-invasive Electroceutical therapeutic device designed for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Beyond SofPulse, Endonovo Therapeutics is exploring the application of its Electroceuticals medical device for treating a range of conditions, including cardio chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular, peripheral artery disease (PAD), and ischemic stroke. The company's business model centers on the development, manufacturing, and marketing of these devices to healthcare providers and patients. Endonovo Therapeutics operates primarily in the United States, with potential for future expansion into international markets as regulatory approvals are secured for its various applications.

ENDV的投资论点是什么？

Endonovo Therapeutics operates in the electroceuticals market, a growing segment within regenerative medicine. The company's focus on non-invasive devices offers a potential advantage over traditional treatments. The SofPulse device addresses a significant market for palliative treatment of soft tissue injuries and chronic wounds. However, the company's financial performance, as indicated by a negative P/E ratio of -0.04 and a market cap of $0.00B, raises concerns about its current profitability and valuation. The high beta of -9.79 suggests significant volatility. Future growth depends on successful clinical trials and regulatory approvals for its expanded applications, including cardiovascular and liver diseases. Investors should carefully consider the risks associated with OTC-traded companies and the uncertainty surrounding the company's long-term financial viability.

ENDV在哪个行业运营？

Endonovo Therapeutics operates within the biotechnology industry, specifically focusing on the electroceuticals market. This market is experiencing growth driven by increasing demand for non-invasive therapies and advancements in medical device technology. The competitive landscape includes companies developing similar electroceutical devices and traditional pharmaceutical companies offering alternative treatments. Endonovo's success depends on its ability to differentiate its products, secure regulatory approvals, and establish strong market presence. The biotechnology industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition.

Biotechnology

Healthcare

ENDV有哪些增长机遇？

Expansion of SofPulse Applications: Endonovo Therapeutics has the opportunity to expand the applications of its SofPulse device beyond its current indications. The market for chronic wound care is estimated to reach billions of dollars, and SofPulse could capture a significant share with successful clinical trials and marketing efforts. Timeline: Ongoing clinical trials with potential results within the next 12-24 months.
Treatment of Cardio Chronic Kidney Disease: The company is exploring the use of its Electroceuticals medical device for the treatment of cardio chronic kidney disease. This represents a significant market opportunity, as chronic kidney disease affects millions of people worldwide. Successful development and commercialization of this application could drive substantial revenue growth. Timeline: Pre-clinical and early clinical trials ongoing, with potential for Phase 2 trials within 2-3 years.
Treatment of Liver Disease NASH: Endonovo Therapeutics is also targeting liver disease non-alcoholic steatohepatitis (NASH) with its Electroceuticals technology. NASH is a growing health concern with limited treatment options, presenting a substantial market opportunity. Timeline: Pre-clinical studies underway, with potential for clinical trials in 3-5 years.
Cardiovascular and Peripheral Artery Disease (PAD) Applications: The company is investigating the use of its Electroceuticals device for cardiovascular and peripheral artery disease (PAD). These conditions affect a large segment of the population, and a non-invasive treatment option could be highly valuable. Timeline: Early-stage research and development, with potential for pre-clinical studies in 2-3 years.
Ischemic Stroke Treatment: Endonovo Therapeutics is exploring the application of its Electroceuticals technology for the treatment of ischemic stroke. Stroke is a leading cause of disability and death, and new treatment options are urgently needed. Timeline: Early-stage research and development, with potential for pre-clinical studies in 3-5 years.

Market capitalization of $0.00B indicates a micro-cap company with limited resources and higher risk.
Negative P/E ratio of -0.04 reflects the company's current lack of profitability.
Beta of -9.79 suggests an inverse correlation with the market, but also indicates high volatility.
The company's focus on electroceuticals positions it in a growing segment of the regenerative medicine market.
SofPulse device targets a significant market for palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain.

ENDV提供哪些产品和服务？

Develops non-invasive Electroceutical medical devices.
Manufactures Electroceutical devices for regenerative medicine.
Distributes Electroceutical devices to healthcare providers and patients.
Offers SofPulse, a therapeutic device for soft tissue injuries, chronic wounds, and post-operative pain.
Researches and develops new applications for Electroceutical technology.
Targets treatment of cardio chronic kidney disease, liver disease NASH, cardiovascular, PAD, and ischemic stroke.

ENDV如何赚钱？

Develops and patents Electroceutical medical device technology.
Manufactures and distributes SofPulse for palliative treatment.
Seeks regulatory approvals for expanded applications of Electroceuticals.
Partners with healthcare providers for product adoption and distribution.

Hospitals and clinics
Physicians and medical professionals
Patients with soft tissue injuries, chronic wounds, and post-operative pain
Patients with cardio chronic kidney disease, liver disease NASH, cardiovascular, PAD, and ischemic stroke (future)

Proprietary Electroceutical technology
Patents protecting device designs and applications
First-mover advantage in specific electroceutical applications
Potential for strong brand recognition with successful clinical outcomes

什么因素可能推动ENDV股价上涨？

Upcoming: Clinical trial results for SofPulse in treating chronic wounds.
Upcoming: Regulatory approvals for expanded applications of Electroceuticals in cardiovascular disease.
Ongoing: Research and development of new Electroceutical devices for regenerative medicine.
Ongoing: Partnerships with healthcare providers for product adoption and distribution.
Ongoing: Expansion into international markets.

ENDV的主要风险是什么？

Potential: Failure to obtain regulatory approvals for new applications.
Potential: Competition from established pharmaceutical companies and medical device manufacturers.
Potential: Negative clinical trial results for SofPulse or other Electroceutical devices.
Ongoing: Limited financial resources and lack of profitability.
Ongoing: Risks associated with OTC market trading, including low liquidity and potential for price manipulation.

ENDV的核心优势是什么？

Proprietary Electroceutical technology
Non-invasive treatment approach
Potential for expanded applications
Focus on regenerative medicine

ENDV的劣势是什么？

Limited financial resources
Lack of profitability
Dependence on regulatory approvals
OTC market trading

ENDV有哪些机遇？

Expansion into new therapeutic areas
Partnerships with healthcare providers
International market expansion
Growing demand for non-invasive therapies

ENDV面临哪些威胁？

Competition from established pharmaceutical companies
Regulatory hurdles and delays
Technological advancements by competitors
Negative clinical trial results

ENDV的竞争对手是谁？

Affymetrix, Inc. — Focuses on genetic analysis and diagnostics, competing in broader healthcare market. — (AFFY)
Ambis Corp — Unknown differentiation due to limited information. — (AMBS)
BioSpecifics Technologies Corp. — Focuses on collagenase-based therapies, competing in wound care. — (BSSP)
Cannabics Pharmaceuticals Inc. — Develops cannabinoid-based therapies, competing in pain management. — (CNBX)
Genlink, Inc. — Unknown differentiation due to limited information. — (GNLKQ)

Key Metrics

MoonshotScore: 43/100

AI Insight

AI analysis pending for ENDV

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Endonovo Therapeutics, Inc. do?

Endonovo Therapeutics, Inc. is a biotechnology company that develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. Its primary product, SofPulse, is designed for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain. The company is also exploring the use of its Electroceuticals technology for treating cardio chronic kidney disease, liver disease NASH, cardiovascular, PAD, and ischemic stroke. Endonovo's business model centers on developing and commercializing these devices to improve patient outcomes and address unmet medical needs.

What do analysts say about ENDV stock?

AI analysis is currently pending for ENDV. Given the company's OTC listing, limited financial information, and lack of profitability, analysts may express caution regarding its investment potential. Key valuation metrics, such as the negative P/E ratio, reflect the company's current financial challenges. Growth considerations will likely focus on the successful development and commercialization of its Electroceutical devices and the achievement of regulatory approvals for expanded applications. The high beta suggests significant volatility, which could deter risk-averse investors.

What are the main risks for ENDV?

The main risks for Endonovo Therapeutics, Inc. include its limited financial resources, lack of profitability, and dependence on regulatory approvals for its Electroceutical devices. Competition from established pharmaceutical companies and medical device manufacturers poses a significant threat. Negative clinical trial results for SofPulse or other devices could severely impact the company's prospects. As an OTC-traded company, ENDV faces risks associated with low liquidity, potential price manipulation, and limited regulatory oversight. Investors should carefully consider these risks before investing in ENDV.